New Zealand at a glance
- Population
- 5.3 million 2025
- Life expectancy at birth
- 82.0 years, 2024
- People aged 65 and over
- 17.6 % of people, 2025
- Health spending per person
- 5,022 US$ per person, 2024
- Doctors
- 3.61 per 1,000 people, 2022
Updated
Reviewed by Chandani Patel
New Zealand AAV Gene Therapy Market Industry Trends and Forecast to 2034: Segmented by (Indication, Route, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$201.7 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $40.0 Mn | — | — |
| 2025 (base) | $48.0 Mn | +$8.0 Mn | — |
| 2026 (forecast) | $57.7 Mn | +$9.7 Mn | +20.1% |
| 2027 (forecast) | $69.3 Mn | +$11.6 Mn | +44.2% |
| 2028 (forecast) | $83.2 Mn | +$13.9 Mn | +73.2% |
| 2029 (forecast) | $99.9 Mn | +$16.7 Mn | +108.1% |
| 2030 (forecast) | $120.0 Mn | +$20.1 Mn | +149.9% |
| 2031 (forecast) | $144.1 Mn | +$24.1 Mn | +200.1% |
| 2032 (forecast) | $173.1 Mn | +$29.0 Mn | +260.4% |
| 2033 (forecast) | $207.9 Mn | +$34.8 Mn | +332.9% |
| 2034 (forecast) | $249.7 Mn | +$41.8 Mn | +419.9% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $48.0 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $249.7 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 20.1% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Indication, route and end user (see all) |
| Key players | Novartis AG, Sarepta Therapeutics, BioMarin, CSL Behring, Ultragenyx and 1 more (see all) |
| Regulator in New Zealand | MedsafeSource: Medsafe. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
AAV gene therapies use harmless adeno-associated viruses to deliver working genes into cells, often as a one-time treatment.
Key segments of the AAV Gene Therapy market include indication (Neuromuscular Diseases, Hemophilia and Eye Diseases) and route (Intravenous, Subretinal and Intrathecal).
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the AAV Gene Therapy market.
Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the AAV Gene Therapy market.
Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the AAV Gene Therapy market. Payers are still working out how to pay for one-time cures.
The AAV Gene Therapy market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Medsafe, part of the Ministry of Health, approves medicines before they can be sold.[1] Pharmac decides which medicines and medical devices the public health system pays for.[2]
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for AAV Gene Therapy. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in New Zealand.
What doctors and scientists are doing in AAV Gene Therapy right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 22 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 22 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 22 Nov 2026.
New Zealand · 2 shared keywords
New Zealand · 1 shared keyword
New Zealand · 1 shared keyword
New Zealand · 1 shared keyword
New Zealand · 1 shared keyword
New Zealand · 1 shared keyword
Digital Health · New Zealand
Healthcare Services · New Zealand
Healthcare Services · New Zealand
Medical Devices · New Zealand
Digital Health · New Zealand
Medical Devices · New Zealand